P R O G R A M
asian interchangeon diabetes
30–31 July in Bangkok, Thailand
Venue
Centara Grand at Central World
2 | A S I A N I N T E R C H A N G E O N D I A B E T E S
ACROSS T2D
Your gateway to the international expert forum for Type 2 Diabetes
ACROSS T2D is a global academy for cardiovascular risk, outcomes and safety studies in Type 2
Diabetes (T2D). It has been established as a collaboration with leading international experts to
provide education and share best clinical practice among professionals who manage patients with
Type 2 Diabetes (T2D). For more information visit us at: www.across-t2d.com
Physicians’ Academy for Cardiovascular Education (PACE-CME) foundation
The rationale for establishing the PACE foundation, the Physicians’ Academy for Cardiovascular
Education foundation comes from the recognition that physician education plays an increasingly
important role in our efforts to reduce the burden of cardiovascular disease and diabetes. The goal
of PACE is to help physicians assimilate the proven findings of scientific research into the day-to-
day practice of clinical medicine, all in the interest of improving outcomes in patients.
The mission of PACE-CME is to improve the cardiovascular health of patients by providing an
international forum for the review, exchange and assimilation of new important data underlying
cardiovascular disease and diabetes and accelerate the translation of this information into clinical
practice. For more information visit us at: www.PACE-CME.org
BANGKOK2016JULY 30 & 31
3 0 – 3 1 J U L Y , B A N G K O K , T H A I L A N D | 3
Bangkok, July 2016
On behalf of Boehringer Ingelheim (S) Pte Ltd, ACROSS T2D and the PACE foundation,
we welcome you to the 3rd Asian Interchange on Diabetes:
Innovation in T2DM: How will novel interventions impact clinical care?
Diabetes Clinical Innovation
Diabetes and Cardiovascular disease (CVD) have continued to rise to epidemic
proportions throughout the world, despite improvements in our understanding and
management of these diseases. Patients with diabetes have a high lifetime CVD risk, thus
management of these patients should not only focus on control of glycaemia but also
address CV risk factors. The conventional approach to managing CVD is aimed at treating
the major CV risk factors: diabetes, hypertension, dyslipidaemia, obesity and smoking as
separate entities, without understanding how a combination of these can multiply the CV
risk. Furthermore, a considerable treatment gap between evidence and practice exists
because guidelines recommendations are not adequately implemented. Newer classes
of glucose lowering drugs have been developed in recent years. Several ongoing and
recently published trials provide guidance that the incretin axis directly or indirectly can
lower CVD risk in diabetes. Recently trials with DPP4 inhibitors suggested that oral gliptin
therapy is safe in CVD but did not lower CVD risk in the short term. Results of longer term
studies with other DPP4 inhibitors and GLP-1 analogue therapies are awaited. Novel data
from the new class of SGLT2 inhibitors showed in the EMPA-REG OUTCOME trial positive
outcomes on the primary endpoint, which included a reduction in CV mortality. During
this Asian Interchange on Diabetes you will receive a balanced review on how all these
novel developments might impact your clinical practice in managing your patients with
T2DM.
Asian Interchange on Diabetes – PACE-CME & ACROSS T2D
This Asian Interchange on Diabetes is in collaboration with PACE-CME (Physicians’
Academy for Cardiovascular Education) and ACROSS T2D (Academy for Cardiovascular
Risk, Outcomes and Safety Studies in Type 2 Diabetes). The mission of PACE-CME is
to improve the cardiovascular health of patients by providing an international forum for
the review, exchange and assimilation of new important data underlying cardiovascular
disease and diabetes and accelerate the translation of this information into clinical
practice.
We wish you an interesting and stimulating meeting.
PACE-CME Foundation
4 | A S I A N I N T E R C H A N G E O N D I A B E T E S
Program itinerary
Friday July 29, 2016
Arrivals All day
Saturday July 30, 2016
Scientific session 08:30 – 10:30 hrs Ballroom A&B
Coffee break 10:30 – 11:00 hrs Foyer
Scientific session 11:00 – 12:30 hrs Ballroom A&B
Lunch 12:30 – 13:30 hrs Delegates Café
Workshops 13:30 – 15:00 hrs Ballroom A&B, Lotus Suite 11,
Lotus Suite 12
Sunday July 31, 2016
Scientific session 09:00 – 11:00 hrs Ballroom A&B
Coffee break 11:00 – 11:30 hrs Foyer
Optional lunch 11:30 – 13:00 hrs Delegates Café
Departures Lobby
3 0 – 3 1 J U L Y , B A N G K O K , T H A I L A N D | 5
Address
Centara Grand & Bangkok Convention Centre at CentralWorld
999/99 Rama 1 Road, Pathumwan
Bangkok 10330, Thailand
Check in time: 14:00 hrs
Check out time: 12:00 hrs
Breakfast: 06:00 – 10:30 hrs, The World Restaurant, level 24
6 | A S I A N I N T E R C H A N G E O N D I A B E T E S
Educational Agenda
Saturday, July 30, 2016
Co-chairmen:
Sompongse Suwanwalaikorn, MD – Chulalongkorn University, Bangkok, Thailand
David Fitchett, MD – University of Toronto, Canada
08:30 – 08:40 Introduction and educational objectives
08:40 – 09:05 Diabetes in Asia: What is different from the west?
Chaicharn Deerochanawong, MD – Rajavithi Hospital College of Medicine,
Bangkok, Thailand
09:05 – 09:40 Management of hyperglycemia in type 2 diabetes:
Update on novel trends and developments
Richard E. Pratley, MD – Florida Hospital Diabetes Institute, Orlando, Fl, USA
09:40 – 10:15 Need for ongoing clinical innovation in management of T2DM:
A closer look at the development process of new entities
Michael Mark, MD, Boehringer Ingelheim – Cardiometabolic Diseases Research
10:15 – 10:30 Panel discussion
All faculty
10:30 – 11:00 Coffee break
Co-chairmen:
Sompongse Suwanwalaikorn, MD – Chulalongkorn University, Bangkok, Thailand
Richard E. Pratley, MD – Florida Hospital Diabetes Institute, Orlando, Fl, USA
11:00 – 11:35 Diabetes and Cardiovascular Disease:
A review of new outcome data impacting practice
David Fitchett, MD – University of Toronto, Canada
11:35 – 12:10 Understanding Diabetes Kidney Disease:
What are the best options for clinical management?
Per-Henrik Groop, MD – University of Helsinki, Helsinki, Finland
3 0 – 3 1 J U L Y , B A N G K O K , T H A I L A N D | 7
12:10 – 12:30 Open forum
All faculty
12:30 – 13:30 Lunch break
WORKSHOPS - CASE DISCUSSIONS
13:30 – 15:00 The clinical challenge of innovations in T2DM
management
International experts will discuss based on practical case studies the
implications of novel developments for patient care
Sunday, July 31
MEET THE EXPERTS
09:00 – 09:30 Update on DPP4 inhibition in T2DM: Implications from
recent and ongoing trials
Richard E. Pratley, MD
09:30 – 09:55 CV Protection in the EMPA-REG OUTCOME Trial:
A ‘Thrifty Substrate’ Hypothesis
Michael Mark, MD
09:55 – 10:25 Update on SGLT2 inhibition in T2DM: A closer look at
EMPA-REG OUTCOME
David Fitchett, MD
10:25 – 11:00 DEBATE
Individualizing the Management of T2DM: who and how?
Based on provocative statements reflecting current and future
management of T2DM in Asia the panel will have an interactive
debate
11:00 Coffee break & end of program
8 | A S I A N I N T E R C H A N G E O N D I A B E T E S
David Fitchett
Lectures:
• Diabetes and Cardiovascular Disease: A review of new outcome
data impacting practice
• Update on SGLT2 inhibition in T2DM: A closer look at EMPA-REG
OUTCOME
Dr. David Fitchett MA MB BChir MD(Cantab) MRCP(UK) FRCP(C) FACC FESC
graduated from Cambridge University in the UK in 1970, and continued
his clinical training at The Middlesex Hospital Medical School, London. His
cardiology training was at The Brompton and Hammersmith Hospitals where
he completed his MD thesis in Clinical and Experimental Studies of Heart
Muscle Disorders. In 1978 he went to The Royal Victoria Hospital, Montreal
where he was director of the CCU and medical director of the cardiac
transplant program.
He is a fellow of the American College of Cardiology, The European Society
of Cardiology and of the Royal College of Physicians of Canada.
In 1997 he came to St Michael’s Hospital in Toronto as Director of the Cardiac
ICU. He remained in that role until 2008.
Dr Fitchett has over 230 reviewed publications, abstracts, and book
chapters. He is a reviewer for many journals including the New England
Journal of Medicine, Circulation, American Heart Journal, Nature Medicine,
and the Canadian Journal of Cardiology. His research interests are clinical
trials in acute coronary syndromes, and the impact of diabetes and metabolic
syndrome on heart disease.
He is the chair of the macrovascular section of the Canadian Diabetes
Guidelines. He is on the steering and on data and safety committees for a
number of international clinical trials.
Currently Dr Fitchett is an Associate Professor of Medicine at the University
of Toronto and a Staff Cardiologist at St Michael’s Hospital.
University of Toronto,
Toronto, Canada
3 0 – 3 1 J U L Y , B A N G K O K , T H A I L A N D | 9
Sompongse Suwanwalaikorn
Associate Professor Sompongse Suwanwalaikorn is Deputy Medical Service
Director in the Division of Endocrinology and Metabolism, Department of
Medicine at Chulalongkorn University, Chulalongkorn Hospital, Bangkok,
Thailand. He trained at Mahidol University and Ramathibodi Hospital
in Thailand and continued his post-graduate training specialising in
Endocrinology and Metabolism in the USA at The Diabetes Institutes, Eastern
Virginia Medical School, Virginia and at the University of Massachusetts
Medical Center, Massachusetts respectively.
Associate Professor Suwanwalaikorn’s academic and research interest have
been focused in the areas of diabetes and thyroid disease, both of which
he has published work in academic journals. In addition to his academic
research interests Associate Professor Suwanwalaikorn is an active member
of a number of professional medical societies pertinent to his interest in
endocrinology and diabetes including The Endocrine Society of Thailand,
The ASEAN Federation of Endocrine Society (AFES), The American Diabetes
Association (ADA) as well as The Royal College of Physicians of Thailand.
Associate Professor Suwanwalaikorn is also a member of the Thai Medical
Council.
Division of
Endocrinology and
Metabolism
Chulalongkorn
University, Bangkok,
Thailand
1 0 | A S I A N I N T E R C H A N G E O N D I A B E T E S
Chaicharn Deerochanawong
Lecture:
• Diabetes in Asia: What is different from the west?
Chaicharn Deerochanawong holds a position as a Professor of Medicine in
Diabetes and Endocrinology Unit at Rajavithi Hospital, College of Medicine,
Rangsit University, Bangkok, Thailand. Currently, he is Scientific Chairman
of the Endocrine Society of Thailand, Secretary and committee member of
the Thai Obesity Association, and a committee member of both the Thai
Atherosclerosis Association and the Royal College of Physicians of Thailand.
Prof. Chaicharn Deerochanawong undertook his clinical and research training
in Diabetes and Endocrinology at the University of Newcastle Upon Tyne,
United Kingdom.
He graduated his Medicine from Chulalongkorn University.In 1992, he
received grant fellowship of Diabetes and Endocrinology in UK by British
Council and in 1996, he received ‘Distinguished research award from ‘Thai
Endocrine Society’. His scientific interests lie in both clinical and research
particularly in the field of diabetes especially diabetes in pregnancy, obesity
and dyslipidaemia.
He was the Principle Investigator Thailand site of HAPO study
(Hyperglycemia and Adverse Pregnancy Outcomes). During his career,
Prof. Chaicharn Deerochanawong has presented and lectured at numerous
meetings both local and international and contributed to many publications,
including over 80 scientific articles.
Rajavithi Hospital
College of Medicine
Bangkok, Thailand
3 0 – 3 1 J U L Y , B A N G K O K , T H A I L A N D | 1 1
Richard E. Pratley
Lectures:
• Management of hyperglycemia in type 2 diabetes: Update on
novel trends and developments
• Update on DPP4 inhibition in T2DM: Implications from recent
and ongoing trials
Dr. Richard Pratley is the Medical Director of the Florida Hospital Diabetes
Institute (FHDI). He is also Senior Faculty at the Translational Research
Institute for Metabolism and Diabetes, as well as a Professor at the Sanford-
Burnham Medical Research Institute at Lake Nona in Orlando, Florida.
Dr. Pratley has served as Head of the Diabetes and Metabolism Unit of
the National Institutes of Health Clinical Diabetes and Nutrition Section
in Phoenix, Arizona. He then took a position as Senior Director in the
Cardiovascular and Metabolism Therapeutic Area at Novartis Pharmaceuticals
where he worked on the clinical development of new drugs for diabetes. From
2004 to 2011, Dr. Pratley was the Director of University of Vermont’s Diabetes
and Metabolism Translational Medicine Unit and a Professor at their College
of Medicine. There he led many large-scale investigations, including NIH and
pharmaceutical company sponsored studies.
As a member of the American Diabetes Association, the European
Association for the Study of Diabetes and The Obesity Society, Dr. Pratley
continues his active involvement in the professional community. The Henry
Christian Award for Excellence in Clinical Research from the American
Federation for Clinical Research Foundation was awarded in recognition of
his work. He regularly presents at national and international meetings, has
written over 150 peer-reviewed articles and is a Principal Investigator for both
NIH and pharmaceutical company sponsored trials in diabetes. He is on the
editorial boards of Diabetes Care and Current Diabetes Reports and acts
as an ad hoc reviewer for many journals, including the American Journal of
Cardiology and Diabetes.
Dr. Pratley is a graduate of Wayne State University School of Medicine
in Detroit, Michigan, and trained in internal medicine at the University of
Michigan in Ann Arbor. He completed Fellowship training in geriatrics and
gerontology at the University of Michigan, Johns Hopkins University, and the
National Institutes of Health (NIH) National Institute on Aging in Baltimore,
Maryland. His current research interests include the prevention of diabetes,
improving the care for persons with diabetes, developing new drugs to treat
and prevent diabetes and its complications and understanding the role of the
fat cell in increasing the risk for diabetes and heart disease.
Florida Hospital
Diabetes Institute
Orlando, FL, USA
1 2 | A S I A N I N T E R C H A N G E O N D I A B E T E S
Michael Mark
Lectures:
• Need for ongoing clinical innovation in management of T2DM - A
closer look at the development process of new entities
• CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty
Substrate” Hypothesis
Dr. Michael Mark, PhD is the Vice President and Global Head of
CardioMetabolic Diseases Research at Boehringer Ingelheim, Germany. In
this role, he is responsible for the research and development of innovative
treatments for cardiovascular and metabolic diseases including type 2
diabetes mellitus, obesity, NASH and diabetic microvascular complications
like eye diseases as well as kidney diseases. Educated as pharmacist
Dr Mark is holding a Ph.D. degree in Pharmacology from the University of
Tuebingen in Germany.
Dr Mark has more than 30 years experience in the pharmaceutical industry.
Early in his career, Dr Mark contributed to the discovery and development
of repaglinide, an approved treatment of type 2 diabetes. He pioneered the
discovery of the DPP-4 inhibitor linagliptin (Trajenta) and was instrumental
in the initiation of the preclinical work for the SGLT2 inhibitor empagliflozin
(Jardiance), both compounds globally launched and marketed. Together with
his team he developed a competitive portfolio for cardiometabolic treatment
options with various preclinical and several clinical developments projects
currently ongoing.
Dr Mark has been appointed as Project Coordinator for SUMMIT, an
Innovative Medicines Initiative (IMI)-sponsored European consortium of
19 academic centers and 6 major pharmaceutical partners, which aims to
identify and characterize novel biomarkers and genetic markers for diabetic
complications. Dr Mark authored many peer-reviewed publications and
meeting contributions and also various book chapters. In addition he holds
numerous patents.
Boehringer Ingelheim
– Cardiometabolic
Diseases Research
3 0 – 3 1 J U L Y , B A N G K O K , T H A I L A N D | 1 3
Per-Henrik Groop
Lecture:
• Understanding Diabetes Kidney Disease: What are the best
options for clinical management?
Per-Henrik Groop, MD, DMSc, FRCPE is currently a Professor of Nephrology
(Chair) at the University of Helsinki, Chief Physician at the Division of
Nephrology, Helsinki University Central Hospital and Principal Investigator
of the Finnish Diabetic Nephropathy (FinnDiane) Study at the Folkhälsan
Research Center in Helsinki, Finland. He also acts as a Professor at the Baker
Heart & Diabetes Institute in Melbourne, Australia. He graduated from the
University of Helsinki in 1982 and he defended his thesis on “The relationship
between GIP and beta-cell function in man” at the same university in 1989.
After postdoctoral studies at the Guy’s Hospital, University of London, under
Professor Giancarlo Viberti, he returned to Helsinki to work as a Consultant
of Nephrology.
His research is focused on the dissection of the pathogenesis of diabetic
complications with special emphasis on diabetic nephropathy. In order to
provide a unique set of clinical resources with high power to identify genes
and genetic variants associated with diabetic complications, he initiated
the large, nation-wide FinnDiane Study in 1997. To date this landmark study
comprises 8400 patients with type 1 diabetes and their family members
recruited via a comprehensive network of 92 hospitals and health care
centers throughout Finland. The FinnDiane Research Group represents an
inter-disciplinary team of 45 scientists, post-graduate students and other
personnel.
University of Helsinki
Helsinki, Finland
1 4 | A S I A N I N T E R C H A N G E O N D I A B E T E S
Notes
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3 0 – 3 1 J U L Y , B A N G K O K , T H A I L A N D | 1 5
Project Managers:
Lieke van Heugten: +31 6 27 08 05 86Iris van Kaam: +31 6 22 74 05 10
MEDCON International
The program is managed by MEDCON International bv under the
auspices of the PACE Foundation. For more information please
contact MEDCON International at: Tel + 31 (0)23 5317 357 or e-mail
[email protected], P.O. box 916, 2003 RX, Haarlem,
The Netherlands.
PACE Foundation
c/o MEDCON International, P.O. Box 916, 2003 RX Haarlem,
The Netherlands, www.pace-cme.org
Supported by an educational grant from Boehringer Ingelheim